Categories Earnings, Technology

Coupa Software’s Q2 results beat estimates

Coupa Software (NASDAQ: COUP) beat market estimates for revenue and earnings in the second quarter of 2020, sending shares soaring over 10% in aftermarket hours on Tuesday. Analysts had projected a loss of $0.10 per share on revenue of $85 million.  

Total revenue of $95.1 million was up 54% from the same period last year. GAAP net loss was $20 million, or $0.32 per share, compared to $13.9 million, or $0.24 per share last year. Adjusted net income was $5.3 million, or $0.07 per share.

Subscription revenues grew 51% year-over-year to $83.5 million. Professional services and other revenues jumped 87% to $11.6 million. Quarterly calculated billings rose 57% year-over-year to $108 million.

Also see: Coupa Q2 2020 Earnings Preview

Rob Bernshteyn, Chairman and Chief Executive Officer said, “By extending our leadership standing in Business Spend Management (BSM), we feel well positioned on our path to $1 billion in revenue.”

For the third quarter of 2020, total revenues are expected to be $95.5-96.5 million and adjusted EPS is expected to be $0.05-0.08. Subscription revenues are expected to be $86-87 million while Professional services and other revenues are expected to be approx. $9.5 million.

For the full year of 2020, revenues are expected to be $369-372 million and adjusted EPS is expected to be $0.11-0.16.

Coupa had recently forged partnerships with PayPal (NASDAQ: PYPL) and Citigroup (NYSE: C) with a focus on making business payments more efficient. The company had also last month acquired contract lifecycle management solutions firm Exari to integrate into its BSM platform. 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top